ORCID Profile
0000-0002-4546-2079
Current Organisations
University of Melbourne
,
Austin Health
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Springer Science and Business Media LLC
Date: 06-04-2023
Publisher: Springer Science and Business Media LLC
Date: 30-03-2022
DOI: 10.1007/S00270-022-03116-Z
Abstract: Pulmonary metastasectomy has been widely adopted in the treatment of metastatic disease. In recent years image guided ablation has seen increased use in the treatment of thoracic malignancies. The objective of this study was to evaluate oncological outcomes following percutaneous ablation (PA) of pulmonary metastasis. A comprehensive search of the PubMed, MEDLINE and EMBASE databases from January 2000 to August 2021 was performed to identify studies evaluating patient survival following ablation of lung metastasis. Pooled outcomes have been presented with a random effects model to assess primary outcomes of overall survival, progression free survival and 1-year local control. Secondary outcomes included procedural mortality, major complications, and the incidence of pneumothorax. A total of 24 studies were identified. The pooled median overall survival was 5.13 [95% confidence interval (CI): 4.37-6.84] years, and the 1-, 3-, 5-year progression free survival rates were 53%, 26% and 20% respectively. The 1-year local control rate was 91% (95%CI: 86-95%). Periprocedural mortality was rare (0% 95%CI: 0-1%), as were major complications excluding pneumothorax (1% 95%CI: 1-2%). Pneumothorax developed in 44% of ablation sessions, although only half of these required chest tube placement. Most patients were able to be discharged day one post-procedurally. PA demonstrates high overall, progression free and local tumour survival in patients with lung metastasis. Complications and mortality are also rare. Consideration of its use should be made in a tumour board meeting in conjunction with surgical and radiotherapy perspectives for targeted local control of metastases.
Publisher: Forum Multimedia Publishing LLC
Date: 12-09-2022
DOI: 10.1532/HSF.4873
Publisher: Hindawi Limited
Date: 19-10-2021
DOI: 10.1111/JOCS.16089
Publisher: Springer Science and Business Media LLC
Date: 12-05-2022
DOI: 10.1007/S00270-022-03154-7
Abstract: Haemorrhoidal disease (HD) is a common anorectal disorder which can substantially impair quality of life. Rectal artery embolisation (RAE) is a recently described technique for the management of HD, however, its clinical efficacy and safety are unclear at present. The objective of this systematic review and meta-analysis is to evaluate the clinical outcomes following RAE. The PubMed, MEDLINE and EMBASE databases were searched for studies specifying the management of haemorrhoids with RAE from January 2000 to October 2021. Primary outcomes were: French bleeding score (FBS), Visual analogue scale (VAS) for pain, general quality of life (QoL) score, and the Goligher prolapse score (GPS). Secondary outcomes were technical success, clinical success, postoperative complications, and technical outcomes. A random-effects meta-analysis was conducted. Study heterogeneity was evaluated, and sensitivity analysis was performed. Thirteen eligible studies were identified including 381 patients. Rectal artery embolisation was associated with improvements in the FBS (mean difference [MD] 2.66 95% confidence interval [CI] 2.10-3.23), VAS (MD 1.92 95% CI 1.58-2.27) and QoL (MD 1.41 95% CI 1.20-3.80), although the grade of internal haemerrhoids increased with uncertain clinical significance (MD 0.30 95% CI 0.23-0.36). Technical success was achieved in almost all procedures (99% 95% CI 94-100%) however clinical efficacy was lower (82% 95% CI 73-89%). Procedural duration and radiation exposure were heterogeneous. No major complications occurred. RAE demonstrates early clinical efficacy with low rates of peri-procedural complications or morbidity. RAE is a promising addition to the treatment options available for HD and warrants ongoing research.
Publisher: Springer Science and Business Media LLC
Date: 20-07-2022
No related grants have been discovered for Minhtuan Nguyenhuy.